1
|
Schmidt AH, Sauter J, Schetelig J, Neujahr E, Pingel J. Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry. Best Pract Res Clin Haematol 2024; 37:101541. [PMID: 38490766 DOI: 10.1016/j.beha.2024.101541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 02/27/2024] [Accepted: 02/29/2024] [Indexed: 03/17/2024]
Abstract
Allogeneic hematopoietic stem cell (HSC) transplantation is a curative therapy for many severe blood diseases. As many patients have no suitable family donor, large unrelated donor registries and donor centers have been established in many countries, along with an international system for the provision of unrelated donor HSC products. As an essential part of this system, DKMS operates donor centers in 7 countries with a total of 12.2 million donors and over 114,000 donations so far, and a multinational donor registry. In 2022, DKMS donors contributed 57.5% of all cross-border donations worldwide. In this review, we describe the international system for the provision of unrelated donor HSC products as well as tasks and responsibilities of donor registries and donor centers. We also discuss relevant aspects of DKMS donor centers, namely donor file composition, matching and donation probabilities and actual donations, and the unique multinational approach of the DKMS Registry.
Collapse
Affiliation(s)
- Alexander H Schmidt
- DKMS Group, Tübingen, Germany; DKMS Clinical Trials Unit, Dresden, Germany; DKMS Registry, Tübingen, Germany.
| | | | - Johannes Schetelig
- DKMS Clinical Trials Unit, Dresden, Germany; University Hospital Carl Gustav Carus, Dresden, Germany
| | | | | |
Collapse
|
3
|
Mengling T, Rall G, Bernas SN, Astreou N, Bochert S, Boelk T, Buk D, Burkard K, Endert D, Gnant K, Hildebrand S, Köksaldi H, Petit I, Sauter J, Seitz S, Stolze J, Weber K, Weber M, Lange V, Pingel J, Platz A, Schäfer T, Schetelig J, Wienand E, Geist S, Neujahr E, Schmidt AH. Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS. Bone Marrow Transplant 2020; 56:798-806. [PMID: 33219340 PMCID: PMC7677905 DOI: 10.1038/s41409-020-01138-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 09/18/2020] [Accepted: 11/03/2020] [Indexed: 11/09/2022]
Abstract
The COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry. Especially, we cover the development of PBSC and bone marrow collection figures, donor management including Health and Availability Check (HAC), transport and cryopreservation of stem cell products, donor recruitment and business continuity measures. The total number of stem cell products provided declined by around 15% during the crisis with a particularly strong decrease in bone marrow products. We modified donor management processes to ensure donor and product safety. HAC instead of confirmatory typing was helpful especially in countries with strict lockdowns. New transport modes were developed so that stem cell products could be safely delivered despite COVID-19-related travel restrictions. Cryopreservation of stem cell products became the new temporary standard during the pandemic to minimize risks related to transport logistics and donor availability. However, many products from unrelated donors will never be transfused. DKMS discontinued public offline donor recruitment, leading to a 40% decline in new donors during the crisis. Most DKMS employees worked from home to ensure business continuity during the crisis.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - Julia Pingel
- DKMS, Tübingen, Germany.,DKMS Registry, Tübingen, Germany
| | - Alexander Platz
- DKMS Life Science Lab, Dresden, Germany.,DKMS Stem Cell Bank, Dresden, Germany
| | - Thomas Schäfer
- DKMS Life Science Lab, Dresden, Germany.,DKMS Stem Cell Bank, Dresden, Germany
| | - Johannes Schetelig
- DKMS, Clinical Trials Unit, Dresden, Germany.,Medizinische Klinik I, University Hospital Carl Gustav Carus, Dresden, Germany
| | | | | | - Elke Neujahr
- DKMS, Tübingen, Germany.,DKMS Life Science Lab, Dresden, Germany.,DKMS Registry, Tübingen, Germany.,DKMS Stem Cell Bank, Dresden, Germany.,DKMS, Clinical Trials Unit, Dresden, Germany
| | - Alexander H Schmidt
- DKMS, Tübingen, Germany.,DKMS Life Science Lab, Dresden, Germany.,DKMS Registry, Tübingen, Germany.,DKMS Stem Cell Bank, Dresden, Germany.,DKMS, Clinical Trials Unit, Dresden, Germany
| |
Collapse
|